Study of Rebastinib + Paclitaxel Combination

A Phase 1b/2, Open Label Study of Rebastinib + Paclitaxel Combination for Patients with Advanced or Metastatic Solid Tumors

NCT03601897 is a 2-part open label, Phase 1b/2, multicenter study of Rebastinib (DCC-2036), a novel tyrosine switch control inhibitor, orally administered in combination with Paclitaxel.

Please see the National Institute of Health’s Clinical Trials.gov site for more information: https://clinicaltrials.gov/ct2/show/NCT03601897

Locations of this multicenter clinical trial:
Alphabetically by state and with Primary Investigator noted